Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Stomach Neoplasms 1Pancreatic Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 39Nivolumab 13Cisplatin 12Paclitaxel 11Docetaxel 11Carboplatin 10atezolizumab 9Trastuzumab 9Gemcitabine 9Cyclophosphamide 8fludarabine 7Bevacizumab 7aldesleukin 6durvalumab 5Taxes 5Oxaliplatin 5Magnetic Resonance Spectroscopy 5Leucovorin 5Irinotecan 5Fluorouracil 5130-nm albumin-bound paclitaxel 5avelumab 4Specimen Handling 4Psychiatric Rehabilitation 4Ipilimumab 4Drug Therapy 4Cetuximab 4Capecitabine 4Albumin-Bound Paclitaxel 4tislelizumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Stomach Neoplasms × Sensitivity and Specificity × Thoracic × Clear all
NCT02839954 2016-12-06

CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor

PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Phase 1/2 Unknown
10 enrolled
GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡